Skip to main content

Table 2 Factors associated with hepatocellular carcinoma in the absence of cirrhosis

From: Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis

Variables Univariate analysis Multivariate analysis
OR 95%CI P values OR 95%CI P values
Age > 50 yrs 0.46 0.34–0.62 < 0.0001 0.42 0.25–0.70 < 0.0001
Gender (male) 1.36 0.94–1.98 0.11    
Family history of HCC 2.29 1.27–4.14 0.006 2.91 1.07–7.92 0.037
Diabetes 0.59 0.39–0.89 0.012    
Hyperlipidemia 2.02 1.29–3.16 0.002    
Etiology
 HBV 0.79 0.54–1.13 0.19    
 HCV 1.43 0.92–2.22 0.12    
 Alcohol abuse 0.44 0.23–0.85 0.014    
 NAFLD 6.77 2.0–23.32 0.002    
HBV-DNA ≥ 500 IU/ml 0.79 0.55–1.11 0.18    
Antiviral therapy 1.04 0.69–1.57 0.86    
PVTT at baseline 0.29 0.17–0.51 < 0.0001    
Leukocyte counts ≥4*109/L 2.31 1.79–2.98 < 0.0001    
PLT ≥100*109/L 6.23 4.31–9.02 < 0.0001 6.67 3.32–13.40 < 0.0001
AST ≥ 40 (U/L) 0.52 0.39–0.70 < 0.0001    
γ-GGT ≥ 60 (U/L) 0.57 0.42–0.77 < 0.0001 0.46 0.27–0.78 0.004
TG ≥ 1.71 mmol/L 2.46 1.50–4.02 < 0.0001 2.66 1.18–6.01 0.019
PTA < 70% 0.18 0.11–0.29 < 0.0001    
AFP ≥ 400 ng/ml 1.05 0.76–1.47 0.75    
Child staging    < 0.0001    
A 17.1 5.43–53.88 < 0.0001 5.67 1.34–24.02 0.019
B 2.48 0.73–8.40 0.15    
C (Reference)       
BCLC staging    < 0.0001    
0-A 13.8 4.35–43.77 < 0.0001    
B 10.81 3.38–34.54 < 0.0001    
C 4.52 1.32–15.47 0.016    
D (Reference)       
  1. Abbreviations: PTA Prothrombin activity